Introduction
============

Cancer is a major public health problem in Korea. According to the annual report of the Korea Central Cancer Registry, more than 200,000 people have been diagnosed with cancer every year since 2010, with a steadily increasing cancer incidence \[[@b1-roj-2016-01753]-[@b4-roj-2016-01753]\]. This trend is expected to persist in the future because of population aging, westernized lifestyle, development of diagnostic tools that can detect cancer, and a medical system that encourages cancer screening \[[@b5-roj-2016-01753]-[@b6-roj-2016-01753]\].

As radiation therapy (RT) is an indispensable part of cancer treatment, it is reasonable and necessary to estimate the clinical utilization of RT for understanding the status and development of cancer treatment in Korea. The most up to date official records on the clinical utilization of RT in Korea were reported for the period 1999--2006 \[[@b7-roj-2016-01753]-[@b10-roj-2016-01753]\]. These records were compiled using questionnaire-based methods over a long period and possibly had recall bias. Recently, we reported the findings of a pilot study for the clinical utilization of RT in 2009 and 2013 \[[@b11-roj-2016-01753]\] in order to estimate the feasibility of statistics using claims data from the Health Insurance Review and Assessment Service (HIRA). In previous studies \[[@b7-roj-2016-01753]-[@b11-roj-2016-01753]\], we categorized patients according to the cancer site treated by RT, instead of their primary cancer diagnostic codes. In the present study, the patients were categorized according to their primary cancer codes rather than their metastasis status or the site of treatment. Moreover, a previous study \[[@b11-roj-2016-01753]\] analyzed patients who only had 'C' code diseases. Patients who had ductal carcinoma in situ of the breast or benign brain tumor treated with RT could not be included in the total count of patients who received RT because they are 'D' code diseases and are therefore classified as benign. Consequently, the actual total number of patients who received RT was underestimated. Therefore, in the present study, we analyzed the data from patients having both 'D' code and 'C' code diseases. The aim of the present study was to estimate the clinical utilization of RT in the 2009--2013 period using claims data from the HIRA.

Materials and Methods
=====================

The detailed methods using claims data from the HIRA are described in a previous study \[[@b11-roj-2016-01753]\]. The customized source population criteria for this study are shown in [Table 1](#t1-roj-2016-01753){ref-type="table"}. In this study, we included not only patients with International Classification of Disease 10 (ICD-10) diagnostic codes C00-C97, but also those with diagnostic codes D00-D48 (including carcinoma in situ or benign neoplasms), who were also associated with at least one of the procedure codes related to RT treatment. In our previous study, we categorized the patients who had diagnostic codes for metastasis (C77-79) based on whether they received RT to the metastatic site, irrespective of the patient's primary cancer diagnostic code. However, in this study, the patients were categorized according to their primary cancer codes rather than their metastasis status, even if they had diagnostic codes indicating metastasis. For example, if the patient had code C34 for primary lung cancer and code C79.30 for brain metastasis, the patient was categorized as having primary lung cancer instead of brain metastasis. This method of categorization was to identify the number of patients who underwent RT for their primary cancers. However, if the patient only had a diagnostic code for metastasis, we could not determine the primary cancer diagnosis; therefore, the patient was categorized as 'unknown primary.' If the patient had both C and D diagnostic codes, it was assumed the patient had received RT for the disease with the C diagnostic code.

We analyzed the claims data from the HIRA in order to identify the total number of patients who underwent RT, and the number of patients who received RT by primary cancer diagnosis, gender, and age group between 2009 and 2013 in Korea. In addition, through the classification of the procedure codes ([Table 2](#t2-roj-2016-01753){ref-type="table"}), we estimated the total number of patients who received specific RT modalities, including brachytherapy, intensity-modulated radiation therapy (IMRT), stereotactic radiation therapy (SRT), and proton therapy.

Results
=======

The total number of patients who received RT in 2009, 2010, 2011, 2012, and 2013 were 45,571, 49,593, 54,671, 59,172, and 61,485, respectively ([Fig. 1](#f1-roj-2016-01753){ref-type="fig"}). Among them, the total number of cancer patients (C00-C97) who received RT in 2009, 2010, 2011, 2012, and 2013 were 42,585, 46,248, 50,883, 55,049, and 57,004, respectively. The total numbers of male and female patients who received RT were 20,780/24,791 in 2009, 22,711/26,882 in 2010, 24,872/29,799 in 2011, 27,101/32,071 in 2012, and 27,941/33,544 in 2013 ([Fig. 2](#f2-roj-2016-01753){ref-type="fig"}). The distribution of patients who received RT by cancer diagnosis between 2009 and 2013 is shown in [Table 3](#t3-roj-2016-01753){ref-type="table"}. The five most common cancers treated with RT between 2009 and 2012 were breast, lung, colorectal, liver, and uterine cervical cancers. However, the fifth most common cancer treated with RT in 2013 was prostate cancer instead of uterine cervical cancer. The three leading types of cancer among male patients were lung, colorectal, and liver cancers, and those among female patients were breast, uterine cervical, and lung cancers. Breast cancer patients constituted a quarter of the total number of cancer patients who underwent RT, and approximately half of the female cancer patients. Carcinoma in situ of the breast treated with RT was the most common among the diseases with code 'D.' The benign neoplasms of the meninges and the central nervous system were second and third most common among the diseases with code 'D.'

The distribution of patients who received RT in 2013 based on cancer diagnosis and age group is shown in [Table 4](#t4-roj-2016-01753){ref-type="table"}. The most common cancer was that of the central nervous system for patients aged 20 years or less, while breast cancer was the most common cancer in patients aged 30--50 years, and lung cancer was the most common cancer in patients aged 60 years or more. Similar trends were observed for previous years.

The distribution of patients who received RT with specific modalities is shown in [Table 5](#t5-roj-2016-01753){ref-type="table"}. Because National health insurance had not covered IMRT and proton therapy before 2011, the number of patients who received IMRT and proton therapy before 2011 was not calculated.

Discussion and Conclusion
=========================

This study was conducted to analyze the clinical utilization of RT between 2009 and 2013 in Korea using claims data from the HIRA. The total number of patients who underwent RT increased 4%--10% per year between 2009 and 2013 ([Fig. 1](#f1-roj-2016-01753){ref-type="fig"}). Considering the annual cancer incidence \[[@b1-roj-2016-01753]-[@b4-roj-2016-01753],[@b12-roj-2016-01753]\], although the percentage of patients who underwent RT increased from 23% to 27% during these 5 years, it remained below 30% ([Fig. 3](#f3-roj-2016-01753){ref-type="fig"}). [Table 6](#t6-roj-2016-01753){ref-type="table"} shows the utilization rate of RT, which is defined as the proportion of all cancers with indications for RT by country \[[@b13-roj-2016-01753]-[@b17-roj-2016-01753]\]. This value can be dependent on the distributions of cancer types and stages. According to these reports, about 47%--55% of cancer patients in developed or developing countries would be candidates for RT treatment. Although the optimal utilization rate of RT in Korea was not reported yet, it is estimated to be within the same range. Even though the optimal RT utilization rate has been criticized for potentially overestimating the demand for RT \[[@b18-roj-2016-01753]\], the clinical utilization rate of RT in Korea could be estimated to be much lower than the optimal utilization rate of RT.

Generally, the number of cancer patients who underwent RT for primary cancer increased steadily; however, the number of uterine cervical cancer patients remained approximately at 2,500 during these 5 years. While, the number of prostate cancer patients who received RT notably increased during this period, and consequently, prostate cancer became the fifth most common cancer in 2013 replacing the cervical cancer. This might not only be attributed to the increased prevalence of prostate cancer, but also to the improvement of RT techniques including IMRT or SRT.

In terms of RT modalities, while the numbers of patients who received brachytherapy were similar for each year between 2009 and 2013, the cases receiving IMRT notably increased from 2011 to 2013, and this increase is expected to continue in the future because of national health insurance coverage of IMRT. Similar to IMRT, the number of cases treated with SRT also has steadily increased during these 5 years. Because the claims data from the HIRA only included that of the insured cases and the number of uninsured treatments could not be recorded, the actual number of patients who received proton therapy is expected to be more than the reported number.

In comparison to the results from a previous study \[[@b11-roj-2016-01753]\], differences were observed in the total number of patients who underwent RT in 2009 and 2013. One of the reasons for the difference could be attributed to the different collection time of claims data from the HIRA, considering that some patients' data are registered after 1 or more years. Therefore, the total number of patients who received RT in the same year might not indicate the actual number.

This study could provide useful clinical utilization data for RT in Korea, and we aim to continuously provide the results on the clinical utilization of RT using claims data from the HIRA in the form of an annual report in the future.
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###### 

The customized source population

  List                          Criterion
  ----------------------------- -------------------------------
  Treatment period              01/01/2009--12/31/2013
  Type of healthcare facility   Tertiary, secondary
  Diagnostic code               C00--C97, D00--D48
  Type of insurance             Health insurance, medical aid
  Hospital region               National
  Sex                           Male, female
  Age                           All ages

###### 

Procedure codes related to radiation therapy

  Procedure code             Name of procedure code
  -------------------------- ---------------------------------------
  HD51-HD56                  Teletherapy---single or opposed ports
  HD58-HD59                  Rotational irradiation
  HD61                       3-Dimensional conformal therapy
  HD80-HD89                  Brachytherapy
  HD91                       Total body irradiation
  HD92                       Total body lymph node irradiation
  HD93                       Total skin electron beam therapy
  HD110-HD115, HD211-HD212   Stereotactic radiation therapy
  HD121                      Proton therapy
  HZ271                      Intensity-modulated radiation therapy

###### 

The distribution of cancer patients who underwent radiation therapy based on primary diagnosis between 2009 and 2013

  Category                          Primary diagnosis (diagnostic code)   No. of patients who received radiation therapy                              
  --------------------------------- ------------------------------------- ------------------------------------------------ -------- -------- -------- --------
  Breast                            (C50)                                 11,111                                           12,226   13,724   14,956   15,655
  Gastrointestinal                  Colorectum (C18-C20)                  4,323                                            4,561    5,033    5,004    4,860
                                    Liver (C22)                           2,719                                            2,757    3,015    3,424    3,595
                                    Esophagus (C15)                       1,106                                            1,179    1,236    1,327    1,374
                                    Stomach (C16)                         912                                              1,016    1,077    1,034    1,012
                                    Pancreas (C25)                        566                                              678      780      940      901
                                    Gallbladder & biliary (C23-C24)       691                                              714      772      842      874
                                    Anus (C21)                            146                                              165      188      220      211
                                    Small bowel (C17)                     28                                               35       39       40       42
                                    Other (C26)                           5                                                2        3        4        3
                                    Subtotal                              10,496                                           11,107   12,143   12,835   12,872
  Thoracic                          Lung (C34)                            7,379                                            8,238    8,861    9,285    9,980
                                    Thymus (C37)                          190                                              221      266      235      245
                                    Mediastinum (C38)                     43                                               42       39       46       47
                                    Trachea (C33)                         14                                               21       16       18       17
                                    Other (C39)                           3                                                1        5        2        1
                                    Subtotal                              7,629                                            8,523    9,187    9,586    10,290
  Head & neck                       Larynx (C32)                          730                                              803      761      872      955
                                    Oropharynx (C01, C09-C10)             340                                              398      496      611      588
                                    Oral cavity (C02-C06)                 362                                              412      502      598      583
                                    Nasopharynx (C11)                     307                                              300      409      493      484
                                    Salivary gland (C07-C08)              259                                              276      291      350      344
                                    Hypopharynx (C12-C13)                 287                                              287      361      392      336
                                    Paranasal sinus (C31)                 106                                              144      150      167      148
                                    Nasal cavity (C30)                    81                                               67       96       124      113
                                    Eye & orbit (C69)                     35                                               36       44       52       49
                                    Lip (C00)                             12                                               8        12       9        14
                                    Other (C14)                           7                                                13       19       22       16
                                    Subtotal                              2,526                                            2,744    3,141    3,690    3,630
  Gynecologic                       Uterine cervix (C53)                  2,439                                            2,441    2,450    2,470    2,545
                                    Uterine corpus (C54-C55)              633                                              588      628      715      737
                                    Ovary & tubes (C56)                   143                                              183      206      200      240
                                    Vagina & vulva (C51-C52)              105                                              119      110      114      94
                                    Other (C57-C58)                       7                                                13       13       14       10
                                    Subtotal                              3,327                                            3,344    3,407    3,513    3,626
  Genitourinary                     Prostate (C61)                        1,222                                            1,446    1,937    2,426    2,552
                                    Ureter & bladder (C66-C67)            360                                              429      496      480      523
                                    Kidney (C64-C65)                      294                                              359      426      405      433
                                    Penis & testis (C60, C62-C63)         51                                               65       65       53       66
                                    Other (C68)                           8                                                9        8        13       12
                                    Subtotal                              1,935                                            2,308    2,932    3,377    3,586
  CNS                               Brain (C70-C71)                       1,365                                            1,448    1,386    1,508    1,577
                                    Spinal cord (C72)                     44                                               44       61       57       55
                                    Other (C47)                           29                                               35       47       37       50
                                    Subtotal                              1,438                                            1,527    1,494    1,602    1,682
  Lymphoma                          Non-Hodgkin's lymphoma (C82-C88)      1,056                                            1,203    1,177    1,325    1,316
                                    Hodgkin's disease (C81)               86                                               98       99       108      91
                                    Other (C96)                           6                                                4        21       21       22
                                    Subtotal                              1,148                                            1,305    1,297    1,454    1,429
  Soft tissue                       (C46, C49)                            406                                              506      540      571      619
  Myeloma & plasmacytoma            (C90)                                 324                                              338      315      410      438
  Thyroid                           (C73)                                 305                                              340      357      388      358
  Leukemia                          (C91-C95)                             333                                              367      357      351      352
  Skin                              (C44)                                 205                                              224      240      273      265
  Malignant melanoma                (C43)                                 148                                              159      203      207      214
  Primary bone & cartilage          (C40-C41)                             157                                              179      211      218      169
  Endocrine                         (C74-C75)                             71                                               66       51       76       91
  Unknown primary                   (C45,C48, C76-C80, C97)               1,026                                            1,021    1,284    1,542    1,728
  Total no. of cancer patients      \-                                    42,585                                           46,284   50,883   55,049   57,004
  Carcinoma in situ of the breast   (D05)                                 939                                              1,128    1,355    1,601    1,870
  Benign neoplasm of meninges       (D32)                                 867                                              859      1,013    954      1,027
  Benign neoplasm of CNS            (D33)                                 616                                              639      720      734      731
  Benign neoplasm of endocrine      (D34-D35)                             197                                              260      227      276      300
  Other D code diseases             (D00-D04, D06-D31, D36-D48)           367                                              423      473      558      553
  Total D code patients             \-                                    2,986                                            3,309    3,788    4,123    4,481
  Total                             \-                                    45,571                                           49,593   54,671   59,172   61,485

CNS, central nervous system.

###### 

The number of patients who underwent radiation therapy by cancer diagnosis and age group in 2013

  Primary diagnosis                          No. of patients who received radiation therapy by age group                                               
  ------------------------------------------ ------------------------------------------------------------- ------- -------- -------- -------- -------- --------
  Breast (C50)                               151                                                           1,600   5,705    5,157    2,203    839      15,655
  Colorectum (C18-C20)                       13                                                            146     549      1,366    1,392    1,394    4,860
  Liver (C22)                                4                                                             78      433      1,211    1,106    763      3,595
  Esophagus (C15)                            0                                                             2       55       345      416      556      1,374
  Stomach (C16)                              7                                                             57      134      279      278      257      1,012
  Pancreas (C25)                             1                                                             12      75       238      318      257      901
  Gallbladder & biliary (C23-C24)            0                                                             8       51       213      312      290      874
  Anus (C21)                                 0                                                             7       19       61       58       66       211
  Small bowel (C17)                          1                                                             2       9        11       10       9        42
  Other (C26)                                0                                                             1       0        0        1        1        3
  Subtotal                                   26                                                            313     1,325    3,724    3,891    3,593    12,872
  Lung (C34)                                 13                                                            126     624      2,182    3,280    3,755    9,980
  Thymus (C37)                               5                                                             23      58       56       67       36       245
  Mediastinum (C38)                          7                                                             6       8        11       11       4        47
  Trachea (C33)                              2                                                             0       5        3        2        5        17
  Other (C39)                                0                                                             0       0        0        0        1        1
  Subtotal                                   27                                                            155     695      2,252    3,360    3,801    10,290
  Larynx (C32)                               1                                                             5       36       230      330      353      955
  Oropharynx (C01, C09-C10)                  3                                                             14      80       214      170      107      588
  Oral cavity (C02-C06)                      14                                                            33      88       157      145      146      583
  Nasopharynx (C11)                          19                                                            55      93       150      110      57       484
  Salivary gland (C07-C08)                   19                                                            30      58       101      82       54       344
  Hypopharynx (C12-C13)                      0                                                             1       22       77       124      112      336
  Paranasal sinus (C31)                      4                                                             8       18       40       42       36       148
  Nasal cavity (C30)                         6                                                             9       17       31       25       25       113
  Eye & orbit (C69)                          4                                                             3       10       14       7        11       49
  Lip (C00)                                  0                                                             0       1        3        3        7        14
  Other (C14)                                0                                                             0       1        1        4        10       16
  Subtotal                                   70                                                            158     424      1,018    1,042    918      3,630
  Uterine cervix (C53)                       49                                                            273     603      724      381      515      2,545
  Uterine corpus (C54-C55)                   0                                                             19      106      325      201      86       737
  Ovary & tubes (C56)                        6                                                             12      50       98       55       19       240
  Vagina & vulva (C51-C52)                   2                                                             3       8        17       19       45       94
  Other (C57-C58)                            1                                                             1       0        4        4        0        10
  Subtotal                                   58                                                            308     767      1,168    660      665      3,626
  Prostate (C61)                             0                                                             0       22       265      868      1,397    2,552
  Ureter & bladder (C66-C67)                 2                                                             2       25       65       138      291      523
  Kidney (C64-C65)                           13                                                            14      44       121      114      127      433
  Penis & testis (C60, C62-C63)              13                                                            18      14       7        6        8        66
  Other (C68)                                0                                                             0       0        1        4        7        12
  Subtotal                                   28                                                            34      105      459      1,130    1,830    3,586
  Brain (C70-C71)                            270                                                           150     281      340      298      238      1,577
  Spinal cord (C72)                          15                                                            6       12       6        5        11       55
  Other (C47)                                15                                                            8       6        10       7        4        50
  Subtotal                                   300                                                           164     299      356      310      253      1,682
  Non-Hodgkin's lymphoma (C82-C88)           87                                                            115     211      347      262      294      1,316
  Hodgkin's disease (C81)                    44                                                            15      8        13       4        7        91
  Other (C96)                                6                                                             1       4        3        2        6        22
  Subtotal                                   137                                                           131     223      363      268      307      1,429
  Soft tissue (C46, C49)                     82                                                            61      86       133      120      137      619
  Myeloma & plasmacytoma (C90)               0                                                             11      38       110      146      133      438
  Thyroid (C73)                              8                                                             15      45       92       78       120      358
  Leukemia (C91-C95)                         151                                                           71      51       49       25       5        352
  Skin (C44)                                 4                                                             13      26       41       52       129      265
  Malignant melanoma (C43)                   2                                                             12      32       68       52       48       214
  Primary bone & cartilage (C40-C41)         49                                                            15      26       38       22       19       169
  Endocrine (C74-C75)                        37                                                            4       12       11       13       14       91
  Unknown primary (C45, C48, C76-C80, C97)   30                                                            61      235      463      508      431      1,728
  Total                                      1,160                                                         3,126   10,094   15,502   13,880   13,242   57,004

###### 

The distribution of patients who received radiation therapy according to specific radiation therapy modalities

  Radiation therapy modality              Year                            
  --------------------------------------- ------- ------- ------- ------- -------
  Brachytherapy                           1,441   1,376   1,384   1,401   1,387
  Intensity-modulated radiation therapy   \-      \-      3,113   6,648   6,747
  Stereotactic radiation therapy          4,226   4,894   5,435   5,543   5,945
  Proton therapy                          \-      \-      25      50      33

###### 

List of relevant studies conducted on the utilization rates of radiation therapy by country

  Author                                          Year   Country                                                                                 Optimal utilization rate of radiation therapy (%)
  ----------------------------------------------- ------ --------------------------------------------------------------------------------------- ---------------------------------------------------
  Delaney et al. \[[@b13-roj-2016-01753]\]        2005   Australia                                                                               52.3
  Jaen Olasolo et al. \[[@b14-roj-2016-01753]\]   2007   Spain                                                                                   55.0
  Barton et al. \[[@b15-roj-2016-01753]\]         2014   Australia                                                                               48.3
  Borras et al. \[[@b16-roj-2016-01753]\]         2015   40 European countries                                                                   47.0--53.2
  Rosenblatt et al. \[[@b17-roj-2016-01753]\]     2015   Ghana, Philippines, Tunisia, Serbia, Costa Rica, Romania, Malaysia, Uruguay, Slovenia   47.0--56.0
